The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study

NCT06770296 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pyrotinib low dose group
DRUG: Pyrotinib normal dose group

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]